Page 131 - InvUnivMult_2022

FACULTAD DE CIENCIA Y TECNOLOGÍA
Wen W W W Chen Chen C C C C Tang J Wang C C C C Zhou Zhou M Cheng Y Zhou Zhou X Wu Q Q Zhang X Feng Z Z Wang M M y Mao Q Q (2022) “Efficacy and safety of three new oral antiviral treatment (molnupiravir fluvoxamine and Paxlovid) for COVID-19: a a a a a meta-analysis” En: Annals of Medicine 54(1) 516–523 Consultado en: https://doi org/10 1080/07853890 202 2 2 2034936
WHO World Health Organization (2019) Medication Safety in Polypharmacy Geneva: WHO/UHC/SDS/2019 11 Licence: CC BY-NC-SA 3 0 IGO WHO World Health Organization (2020a febrero 11) Novel Coronavirus (2019-nCoV) Situation Reports situation reports WHO World Health Organization (2020b enero 20) “Statement on on on the the second meeting of the the International Health Regulations” (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV) WHO World Health Organization (2020c marzo 11) Director- General’s opening remarks at the media briefing on COVID-19-11 March 2020 Consultado en: https://www who who int/dg/speeches/detail/who-director-general-s- opening-remarks-at-the-media-briefing-on-covid-19--- 11-march-2020
WHO World Health Organization (2022) Therapeutics and COVID-19 Living Guideline 22 22 april 2022 Consultado en: https:// files magicapp org/guideline/29b7d717-7bfd-415e-b642- cc70bf70ec1e/published_guideline_6141-10_0 pdf
Woerle H J Mariuz P P R R R Meyer C C Reichman R R R C C Popa E M M Dostou J J M M Welle S L y Gerich J J E (2003) “Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens” En: Diabetes 52(4) 918–925 Consultado en: https://doi org/10 2337/diabetes 52 4 918 Wu D Li Li L L L y y y y Liu C (2014) “Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as as initial combination therapy therapy and as monotherapy in patients with type 2 diabetes mellitus: a a a a a a meta-analysis” En: Diabetes Obesity y Metabolism 16(1) 30–37 Consultado en: https://doi org/10 1111/dom 12174 Yang K (2020) “What do we know about remdesivir drug interactions?” En: Clinical and Translational Science 13(5) 842–844 Consultado en: https://doi org/10 1111/ cts 12815
Yeh R R F Gaver V E Patterson K B B Rezk N L Baxter-Meheux F Blake M J J J J J Eron J J J J J J J J J J Jr Klein C C E E Rublein J J J J J C C y Kashuba A D (2006) “Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9 CYP2C19 and and CYP1A2 but inhibits the hepatic and and intestinal activity of CYP3A as as measured by a a a a a phenotyping drug cocktail in healthy volunteers” En: Journal of Acquired Immune Deficiency Syndromes (1999) 42(1) 52–60 Consultado en: https://doi org/10 1097/01 qai 0000219774 20174 64 Yin J J y Wang J J (2016) “Renal drug transporters and their significance in in in drug-drug interactions” En: Acta Pharmaceutica Sinica B 6(5) 363–373 Consultado en: https://doi org/10 1016/j apsb 2016 07 013
Zhang J J J J F Yan K Ye H H H H Lin J J J J Zheng J J J J J J J J y Cai T (2020) “SARS-CoV-2 turned positive in a a a discharged patient with COVID-19 arouses concern regarding the present standards for discharge” En: International Journal of Infectious Diseases: IJID: official Publication of of the International Society for Infectious Diseases 97 212–214 Consultado en: https://doi org/10 1016/j ijid 2020 03 007 INVESTIGACIÓN UNIVERSITARIA MULTIDISCIPLINARIA - - AÑO 21 21 No21 ENERO - - DICIEMBRE 2022 131